Does Rallies show Form 4 insider transactions for OBIO?

Yes. Rallies tracks OBIO insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is OBIO research on Rallies investment advice?

No. Rallies provides research, data, and educational context for OBIO. It does not provide personalized investment advice.

OBIO (Orchestra BioMed Holdings, Inc. Ordinary Shares) Stock Analysis - Insider Trades

Orchestra BioMed Holdings, Inc. Ordinary Shares (OBIO) is a publicly traded Healthcare sector company. As of May 21, 2026, OBIO trades at $3.98 with a market cap of $238.33M and a P/E ratio of -3.57. OBIO moved +0.13% today. Year to date, OBIO is -6.13%; over the trailing twelve months it is +34.92%. Its 52-week range spans $2.20 to $6.50. Analyst consensus is strong buy with an average price target of $13.40. Rallies surfaces OBIO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading OBIO stock inside the company?

Recent OBIO insider activity includes Aryeh Jason bought 665, Aryeh Jason bought 8.97K, Hochman David P bought 5.00K, Fain Eric S bought 20.00K, and RTW INVESTMENTS, LP sold 32. Rallies tracks insider transaction dates, shares, prices, and estimated values.

OBIO Key Metrics

Key financial metrics for OBIO
Metric	Value
Price	$3.98
Market Cap	$238.33M
P/E Ratio	-3.57
EPS	$-1.11
Dividend Yield	0.00%
52-Week High	$6.50
52-Week Low	$2.20
Volume	0
Avg Volume	0
Revenue (TTM)	$33.48M
Net Income	$-52.70M
Gross Margin	99.43%

Recent OBIO Insider Trades

Aryeh Jason bought 665 (~$2.49K) on May 18, 2026.
Aryeh Jason bought 8.97K (~$34.99K) on May 15, 2026.
Hochman David P bought 5.00K (~$18.85K) on May 15, 2026.
Fain Eric S bought 20.00K (~$82.60K) on May 14, 2026.
RTW INVESTMENTS, LP sold 32 (~$132.16) on Apr 27, 2026.

Latest OBIO News

Orchestra BioMed Raises $35M, Targets BACKBEAT Enrollment by Q3 2026 — May 12, 2026
Orchestra BioMed Completes $35M Royalty Financing, Gains $15M from Ligand and $20M from Medtronic — May 6, 2026
Orchestra BioMed’s AVIM Therapy Cuts Systolic BP by 13.2 mmHg, 89% Sustained Control — Apr 23, 2026

OBIO Analyst Consensus

6 analysts cover OBIO: 0 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $13.40.

Common questions about OBIO

Who is trading OBIO stock inside the company?: Recent OBIO insider activity includes Aryeh Jason bought 665, Aryeh Jason bought 8.97K, Hochman David P bought 5.00K, Fain Eric S bought 20.00K, and RTW INVESTMENTS, LP sold 32. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for OBIO?: Yes. Rallies tracks OBIO insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is OBIO research on Rallies investment advice?: No. Rallies provides research, data, and educational context for OBIO. It does not provide personalized investment advice.